Health AI Central
Share:
Peer-Reviewed Publication
BMC Gastroenterol2025;25(1):823.November 20, 2025Journal Article

Altered gut microbial functional pathways in people with irritable bowel syndrome enable precision health insights.

Eric Patridge1, Anmol Gorakshakar1, Matthew M Molusky1, Oyetunji Ogundijo1, Cristina Julian1, Lan Hu1, Grant Antoine2, Momchilo Vuyisich2, Robert Wohlman3, Guruduth Banavar4
1Viome Research Institute, Viome Life Sciences Inc, New York City, NY, USA.
2Viome Research Institute, Viome Life Sciences Inc, Seattle, WA, USA.
3Washington Gastroenterology (WAGI), Seattle, WA, USA.
4Viome Research Institute, Viome Life Sciences Inc, New York City, NY, USA. guru@viome.com.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Functional gastrointestinal disorders present diagnostic and therapeutic challenges, and there is a strong need for molecular markers that enable early health insights and intervention. Herein, we present an approach to assess the gut microbiome with stool-based gut metatranscriptome data from a large adult human population (n = 80,570), using irritable bowel syndrome as an example tha…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.